Intended for healthcare professionals

Letters Rosiglitazone and pioglitazone

Beware fractures

BMJ 2009; 339 doi: (Published 29 September 2009) Cite this as: BMJ 2009;339:b3957
  1. Alok Dixit, assistant professor1,
  2. Pinki Pandey, assistant professor1
  1. 1M M Institute of Medical Science and Research, Mullana, Ambala, India 133203
  1. alkdxt{at}

    Juurlink and colleagues show that pioglitazone has fewer adverse cardiovascular outcomes than rosiglitazone, which may be a class effect.1 However, recent reports show that thiazolidinediones are associated with increased incidence of …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription